Literature DB >> 8090927

Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia.

R J Jackman1, K W Nowels, M J Shepard, S I Finkelstein, F A Marzoni.   

Abstract

PURPOSE: To determine whether histologic findings of cancer or atypical hyperplasia at large-core needle biopsy (LCNB) of nonpalpable breast lesions match histologic findings at excision.
MATERIALS AND METHODS: Stereotaxic LCNB was performed with an automated prone unit, biopsy gun, and 14-gauge cutting needles in 450 nonpalpable breast lesions. Lesions classified as carcinoma or atypical ductal hyperplasia (ADH) at histologic examination after LCNB were excised. A pathologist retrospectively compared core and excisional histologic findings.
RESULTS: Histologic comparison was performed in 116 of 135 carcinomas after LCNB. Histologic findings were concordant in 99 carcinomas. Partial discordance in 17 carcinomas led to an additional surgical procedure in one case. Histologic comparison was performed in 16 of 19 ADHs diagnosed with LCNB. Histologic findings were concordant in five and discordant in 11 ADHs.
CONCLUSION: LCNB findings of carcinoma are accurate and allow definitive therapeutic surgery, including mastectomy. LCNB findings of ADH are inaccurate, and excisional biopsy is necessary.

Entities:  

Mesh:

Year:  1994        PMID: 8090927     DOI: 10.1148/radiology.193.1.8090927

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  26 in total

1.  The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions.

Authors:  A E Ibrahim; A C Bateman; J M Theaker; J L Low; B Addis; P Tidbury; C Rubin; M Briley; G T Royle
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

2.  Will the spectrum of lesions prompting a "B3" breast core biopsy increase the benign biopsy rate?

Authors:  P J Carder; J C Liston
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

3.  Experience in large-core needle biopsy in the diagnosis of 1431 breast lesions.

Authors:  Xi Wei; Ying Li; Sheng Zhang; Ying Zhu; Yu Fan
Journal:  Med Oncol       Date:  2010-03-26       Impact factor: 3.064

4.  Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.

Authors:  Hans-Peter Sinn; Zeinab Elsawaf; Birgit Helmchen; Sebastian Aulmann
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

5.  Role of ultrasound and sonographically guided core biopsy in the diagnostic evaluation of ductal carcinoma in situ (DCIS) of the breast.

Authors:  V Londero; C Zuiani; A Furlan; J Nori; M Bazzocchi
Journal:  Radiol Med       Date:  2007-09-20       Impact factor: 3.469

Review 6.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

7.  Ultrasound-guided Tru-cut biopsy of the breast.

Authors:  N P Woodcock; I Glaves; D R Morgan; J MacFie
Journal:  Ann R Coll Surg Engl       Date:  1998-07       Impact factor: 1.891

8.  Factors associated with upstaging of ductal carcinoma in situ diagnosed by core needle biopsy using imaging guidance.

Authors:  Cholatip Wiratkapun; Pachara Patanajareet; Bussanee Wibulpholprasert; Panuwat Lertsithichai
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

9.  Surgical biopsy findings in patients with atypical hyperplasia diagnosed by stereotaxic core needle biopsy.

Authors:  I Tocino; B M Garcia; D Carter
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

10.  Mammographically detected breast cancer. Benefits of stereotactic core versus wire localization biopsy.

Authors:  J H Yim; P Barton; B Weber; D Radford; J Levy; B Monsees; F Flanagan; J A Norton; G M Doherty
Journal:  Ann Surg       Date:  1996-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.